Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14592866 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2OPRM1OPRL1KDM4ELMNA | |
| SCHEMBL13096629 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL14437847 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL10226990 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL248285 | 0.69 | — | — | |
| SCHEMBL8552663 | 0.68 | SMN1; SMN2 (0.52) | SMN1; SMN2OPRM1OPRL1KDM4ELMNA | |
| SCHEMBL14213200 | 0.67 | — | — | |
| SCHEMBL4289914 | 0.67 | SMN1; SMN2 (0.50) | SMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL21042654 | 0.67 | SMN1; SMN2 (0.56) | SMN1; SMN2OPRM1OPRL1KDM4ELMNA | |
| SCHEMBL24004291 | 0.66 | SMN1; SMN2 (0.39) | SMN1; SMN2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207353-A1 | USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019243850-A1 | OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262187-B2 | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-06-07 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149536-A1 | Inhibitors of Akt activity | AKT1, AKT2, AKT3 | SMN1; SMN2 3892/4885OPRM1 4231/4885OPRL1 4118/4885 |
| US-11236111-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | SMN1; SMN2 4688/4885OPRM1 3875/4885OPRL1 4229/4885 |
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | SMN1; SMN2 2514/4885OPRM1 39/4885OPRL1 74/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | SMN1; SMN2 3055/4885OPRM1 3757/4885OPRL1 4276/4885 |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BPHL, KLK3, DNPEP | SMN1; SMN2 3213/4885OPRM1 1966/4885OPRL1 529/4885 |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | SMN1; SMN2 4688/4885OPRM1 3875/4885OPRL1 4229/4885 |
| US-20070082906-A1 | Inhibitors of akt activity | AKT2, AKT1, AKT3 | SMN1; SMN2 3880/4885OPRM1 4411/4885OPRL1 3986/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | SMN1; SMN2 2514/4885OPRM1 39/4885OPRL1 74/4885 |
| US-20240207353-A1 | USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS | VIP, GRPR, ITCH | SMN1; SMN2 3400/4885OPRM1 206/4885OPRL1 73/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | SMN1; SMN2 3497/4885OPRM1 4440/4885OPRL1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.